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It has been demonstrated  from several  laboratories  that  there  exists  a  number of 
antigen-nonspecific  soluble  factors  that  can  transmit  signals  for  growth  and/or 
differentiation  among various  types  of leukocytes and  that  thus  play a  potentially 
major  role  in  the  regulation  of  immune  responses  (1,  2).  Certain  studies  have 
demonstrated  that  monocyte-derived interleukin  1  (IL-1) 1 induces  certain  thymus- 
derived T  cell subsets to secrete IL-2, which in turn can maintain  the continuous in 
vitro proliferation  of other T  cell subsets  (3, 4).  In this regard, by using IL-2, it  has 
recently become possible to maintain the long-term culture of antigen-specific mouse 
or human T  cell clones (5-10). 
Compared with the use of IL-1 and IL-2 in T  cell systems, the modulation of bone 
marrow-derived B cell activation, proliferation, and differentiation by soluble factors 
is  poorly understood.  Recent  studies  of the long-term culture  of normal  mouse and 
human  B  cells  have indicated  the  existence  of T  cell-derived  B  cell  growth  factors 
(BCGF) that deliver signals to activated B cells to maintain a proliferative state (11- 
13).  Indeed, we and others have reported that there are separate signals required  for 
B cell proliferation vs. differentiation  in both the mouse and human models (14-17). 
With regard to the sources of human BCGF, we have recently demonstrated  that 
substantial  BCGF activity was contained in culture supernatants  of phytohemagglu- 
tinin  (PHA)-stimulated  human mononuclear cells  (MNC)  (18)  and that  BCGF and 
IL-2 elaborated by mitogen-stimulated peripheral blood T  cells are separate molecules 
(19). Finally, we have most recently developed a human T-T hybridoma that produces 
BCGF in the absence of other demonstrable T  cell factor activity (20). In the present 
study, using this monoclonal BCGF, we have examined the various activation signals 
required  by  purified  human  peripheral  blood  or  tonsillar  B  cells  for  proliferative 
responses to BCGF. The data strongly suggest that  there  are at  least  two subsets  of 
human  B  cells  with  regard  to  their  relative  susceptibility  to  proliferative  signals 
delivered by BCGF, based on their state of in vivo activation. 
1  Abbreviations used in this paper: AET, S-(2-aminoethyl)-isothiuronium bromide hydrobromide; BCE, B 
cell-enriched; BCDF, B cell differentiation factor; BCGF, B cell growth factor; ELISA, enzyme-linked 
immunosorbent assay; FCS, fetal calf serum; IL, interleukin; MNC, mononuclear cells; PBMC, peripheral 
blood mononuclear cells; PHA, phytohemagglutinin; PWM, pokeweed mitogen; SAG, Staphylococcus  aureus 
Cowan I; sIg, surface immunoglobulin. 
530  Journal of Experimental Medicine • Volume 157, February 1983  530-546 A. MURAGUCHI, J.  L.  BUTLER, J.  H.  KEHRL,  AND A.  S.  FAUCI  531 
Materials and Methods 
Reagents.  Purified PHA was obtained from Wellcome Research Laboratories, Beckenham, 
England. Pokeweed  mitogen (PWM) was purchased from Gibco Laboratories, Grand Island 
Biological  Co., Grand Island, NY.  Staphylococcus aureus Cowan I  (SAC)  was prepared in our 
laboratory as previously described in detail (17). F(ab')2 fragment goat anti-/x-specific antibody, 
F(ab')2 fragment nonimmunized  goat IgG, fluorescein-eonjugated  F(ab')2 fragment goat anti- 
/L human immunoglobulin  (Ig) ~, 7, a, heavy, and light chains), fluorescein-eonjugated  F(ab')2 
fragment goat anti-mouse IgG, chromatographically purified human IgG, and human IgM, 
and F(ab')2 fragment rabbit anti-human Ig were purchased from N.  L. Cappel Laboratories 
Inc., Cochranville, PA.  A  monoelonal antibody (4F2)  was  prepared  in  our  laboratory as 
previously described (21, 22). 
Cell Preparations.  Peripheral blood mononuclear cells  (PBMC)  from healthy donors were 
separated  by  the  standard  Hypaque-Ficoll gradient  method  (18).  B  cell-enriched  (BCE) 
populations from PBMC were obtained by depletion of T cells and monocytes (18). Briefly, T 
cells were depleted by twice rosetting with S-(2-aminoethyl)-isothiuronium  bromide hydrobro- 
mide (AET)-treated sheep erythrocytes. Monocytes were depleted by adhering 50 ×  108 T cell- 
depleted cells to plastic flasks containing  RPMI 1640 with 1% fetal calf serum (FCS) for 45 min 
at 37°C. Within this peripheral BCE population, there were 60-80% surface Ig (sIg)-positive 
cells as determined by staining  with a fluorescein-conjugated  F(ab')2 fragment goat anti-human 
Ig, and 8-20% monocytes as determined by nonspecific  esterase staining (23). Thus, sIg-positive 
cells were purified thoroughly by rosetting with ox erythrocytes coated with rabbit anti-human 
Ig (24). Because this procedure reduced the monocytes to <1% and increased sIg-positive cells 
up to 80-90% in the BCE population, these sIg-positive cells were used as purified peripheral 
blood B cells. Human tonsils were obtained at tonsillectomy from 12- to 22-yr-old patients with 
chronic tonsillitis and were dispersed into single-cell suspensions (25). BCE populations from 
tonsillar MNC were obtained by the methods described above. After two depletions of AET 
rosette-forming cells followed  by depletion of plastic-adherent cells, there were 83-92% of sIg- 
positive cells  and <0.1%  of esterase-positive cells.  Thus, this BCE  population was  used  as 
purified tonsillar B cells. In certain experiments where indicated, tonsillar BCE suspensions 
were  separated into fractions according to cell  volume by using counterflow centrifugation- 
elutriation (model J-6B, Beckman Instruments, Inc., Spinco Div., Palo Alto, CA) by the method 
described previously in detail (26) with certain modifications (T. L. Gerrard and A. S. Fauci, 
unpublished observations). Briefly,  500  ×  108 cells  in 3 ml of elutriator buffer (phosphate- 
buffered saline added  with  1.25% of human albumin and  50  /~g/ml of gentamycin) were 
injected into the elutriator chamber and spun with the J-6B elutriator at a constant speed of 
2,020  _  10 rpm, and the countercurrent flow rate was started at  7.5 ml/min and increased 
every 200 ml by 0.5-ml/min increments. Each 50-ml aliquot was collected from the exit part of 
the elutriator centrifuge. Cellular volume was measured with a Coulter Channelyzer (Coulter 
Electronics Inc., Hialeah, FL). Cells that were positive for 4F2 antigen were enumerated by 
treating cells with mouse monoclonal 4F2 antibody followed  by incubating with fluorescein- 
conjugated F(ab')s goat  anti-mouse IgG (27).  Sheep erythrocyte receptor-positive cells were 
enumerated by rosetting the cells with AET-treated sheep erythrocytes (18). 
BCGF Preparations.  Conventional BCGF was  prepared  as  previously described from  the 
supernatants of co-cultures of PBMC from two allogeneic donors in the presence of PHA (18). 
Monoclonal BCGF was obtained from a human T-T cell hybridoma cell line, 2Bll, which had 
been established in our laboratory (20). Cell-free supernatants  were collected from unstimulated 
2Bxl cells or a  subclone of 2Bll, which showed substantial BCGF activity measured by the 
method described previously (18). In this monoclonal BCGF preparation, there was no IL-2 
activity as determined by measurement of [ZH]thymidine incorporation by an IL-2-dependent 
cell line as described by Farrar et al. (28), and there was no T  cell-replacing factor activity as 
determined by measurement of the induction of plaque-forming cells  from SAC-stimulated 
normal B cells as described by Falkoff et al. (17), or from the Epstein-Barr virus-transformed B 
blastoid cell line, CESS, described previously (29). 
B  Cell  Costimulatory Assay.  A  human B  cell  costimulatory assay  was  performed  by  the 
methods described for  the murine model by Howard et  al.  (30),  with slight modifications. 
Briefly,  purified B cells from peripheral blood or tonsillar MNC were cultured in 200/xl of 532  ACTIVATION AND PROLIFERATION OF HUMAN B  CELL SUBSETS 
RPMI  1640 containing  10% FCS (Dutchland  Laboratories, Inc., Denver, PA), 5 ×  10 -5 M  2- 
mercaptoethanol,  penicillin (100/~g/ml),  and streptomycin  (100/~g/ml)  in flat-bottomed 96- 
well microtiter plates  (Costar,  Data  Packaging,  Cambridge,  MA)  at densities as indicated  in 
each experiment. Some cultures contained F'(ab')2 fragment goat anti-human/~ antibody (1-75 
/~g antibody/ml),  F(ab')2  fragment  nonimmunized  goat IgG  (15-150/~g/ml),  soluble human 
IgM or IgG (4-1,000 iug/ml), and/or various dilutions of the BCGF preparation  as indicated. 
Cultures  were  incubated  in  100%  humidity  in  5%  CO2  in  air  at  37°C.  In  the  standard 
proliferation assays,  the cultures were pulsed with  1/~Ci of [3H]thymidine  (6.7  Ci/mM;  New 
England  Nuclear,  Boston,  MA)  over  the  last  16-20  h  of a  3-d  culture.  Incorporation  of 
[3H]thymidine  was  measured  by standard  liquid scintillation counting techniques after har- 
vesting by a Titertek cell harvester (Flow Laboratories, Inc., Rockville, MD). 
Measurement of the  Amount of Ig  in  Culture Supernatants.  Total  IgG  and  IgM  in  culture 
supernatants  were measured  by using enzyme-linked immunosorbent  assays  (ELISA)  as  has 
been previously reported (31). 
Results 
Effect of BCGF on Co-culture of Peripheral Blood B Cells with Soluble Anti-I~ Antibody.  To 
determine the conditions for the co-culture system, 1 ×  105 purified B cells from the 
peripheral blood of normal donors  (enriched by the protocol described in Materials 
and Methods) were cultured with 15/~g/ml of F(ab')2 fraction of goat anti-bt antibody 
in the presence of BCGF (50 or 5% vol/vol). Substantial  proliferation was observed 
only when both goat anti-/~  antibody and BCGF were added to the culture and not 
when either was added alone (Fig.  1, groups E-H). This costimulatory effect of BCGF 
with goat anti-/~  antibody on B cell proliferation was found in the culture with not 
only monoclonal  BCGF but  also  with  conventional  BCGF  (PHA-conditioned  me- 
dium), which was prepared by culturing allogeneic human  MNC  from two donors 
together with PHA for 96 h  as previously described (18).  Purified B cells manifested 
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Incorporation of [3H]thymidine  by purified B cells in response to goat anti-/.t antibody with 
or without BCGF.  1 ×  10  ~ purified B cells from the peripheral blood of normal donors were cultured 
with 15/~g/ml F(ab')2 fragment of goat anti-p, antibody in the presence or absence  of 2B]a (BCGF 
derived from a human T-T cell hybridoma) or PHA-conditioned medium (BCGF prepared by the 
conventional method described  in Materials and Methods)  at a final concentration of 50 or 5% vol/ 
vol. Cultures were incubated for 3 d; [nH]thymidine  was added for the last  16 h. Data represent the 
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of added BCGF of a  magnitude comparable to that of co-culture of anti-# antibody 
and BCGF. No response was observed to the T  cell mitogen, PHA, in the presence or 
absence of added anti-# antibody. 
Specific Binding of Anti-# Antibody to the IgM Receptor on B Cells.  To demonstrate the 
specific interaction  between  F(ab')2 goat anti-IgM antibody and membrane IgM,  1 
X  105 purified peripheral  blood B  cells were co-cultured with F(ab')2 fragment  goat 
anti-# antibody or with nonspecific F(ab')2 fragment goat Ig in the presence of BCGF 
(25%  vol/vol).  Although substantial  B  cell proliferative  responses were observed by 
the co-culture with F(ab')2 fragment  anti-# antibody, no proliferation  was observed 
with F(abr)2 fragment nonspecific goat Ig (Table I, groups E-G). 
In further attempts to define the specific binding of anti-# antibody to membrane 
IgM, we added  soluble  human  IgM and  IgG at  various concentrations  to cultures 
in which  1 ×  105 freshly separated  peripheral  blood  B  ceils  were co-cultured  with 
anti-#  antibody  (15  #g/ml)  and  BCGF  (25%  vol/vol).  Data  in  Fig.  2  demonstrate 
that, although 20 #g/ml of soluble IgM enhanced the incorporation of [aH]thymidine 
of B  cells  that  were stimulated  with  anti-#  antibody and  BCGF,  the  incorporation 
was reduced to background levels with  100 #g/ml or more of soluble IgM. In contrast 
to IgM, the same concentration of IgG did not show any effect on anti-#-stimulated 
B cell proliferation. Furthermore, concentrations of 4-500 #g/ml of IgM had no effect 
on SAC-induced B cell proliferation, ruling out the possibility of nonspecific suppres- 
sion of responses or of toxicity to B  cells by these  concentrations  of IgM  (data  not 
shown). 
Optimal Conditions  for Synergistic Effect of Anti-# Antibody and BCGF on Peripheral Blood 
or  Tonsillar B  Cell  Proliferation.  To  study  the  relationship  between  the  level  of 
proliferative responses of B cells and the concentration of BCGF in culture,  1 ×  105 
purified peripheral blood B cells were cultured with serial dilutions of the monoclonal 
BCGF in the presence of anti-# antibody (15 #g/ml), and proliferation of B cells was 
measured after 3 d of culture. As the concentration of BCGF in culture increased, the 
incorporation of [aH]thymidine by B cells increased to a concentration of 25% vol/vol 
TABLE  I 
Induction of B Cell Proliferation by Costimulation with Goat Anti-# Antibody 
and Monoclonal BCGF 
Co-culture*  Incorporation of  Group 
Antibody  BCGF§  [aH]thymidine:~ 
tlglml  cpm 
A  --  --  259 + 21 
B  --  +  2,342 + 652 
C  F(ab')2 goat anti-/~, 15  --  2,627 + 219 
D  F(ab')2 goat anti-#, 15  +  22,560 + 558 
E  F(ah')2 goat IgG, 15  --  385 +  127 
F  F(ah')2 goat IgG, 15  +  936 +_ 142 
G  F(ab')~ goat IgG, 150  +  958 +  122 
* 106 purified B cells were co-cultured with  antibodies in  the presence or 
absence of BCGF. 
:~ Incorporation of [3H]thymidine was measured on day 3. 
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Fro.  2.  Inhibition of anti-#-induced B cell proliferation by soluble IgM.  1 X  105 purified B cells 
from the peripheral blood of normal donors were cultured with 15 #g/ml of anti-/L antibody alone 
(l-l), anti-/t antibody and 25% vol/vol of BCGF (O), anti-# antibody, BCGF, and various doses of 
inhibitors: soluble IgM (O), soluble IgG (,). Cultures were incubated for 3 d; [3H]thymidine was 
added for the last 16 h. Data represent the mean +  SEM of triplicate experiments. 
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Fio.  3.  The relationship between the level of proliferative responses of B cells and the concentration 
of BCGF.  1 ×  105 purified peripheral blood B cells were cultured with serial dilutions of BCGF in 
the presence (O) or absence (O) of anti-# antibody (15 #g/ml). Cultures were incubated for 3 d; 
[ZH]thymidine was added for the last 16 h. Data represent the mean -  SEM of triplicate experiments. 
of BCGF  in the presence of anti-/~ antibody  (Fig.  3).  Thus,  we  used  the monoclonal 
BCGF  at a  concentration  of 25% vol/vol for the subsequent  costimulatory  assays. 
To study the relationship between B  cell density in the microwell cultures used and 
the magnitude  of proliferative responses of B  cells, various numbers  of purified B  cells A. MURAGUCHI, J.  L.  BUTLER,  J.  H.  KEHRL, AND A.  S.  FAUCI  535 
l0  s 
10  4 
10  3 
A. BACKGROUND 
10  2  ,  ,  i I  , 
10 4  ,,,/,.., 
10 s  10 6 
B. ANTI-~ STIMULATED 
10 4  10  s  10  s 
CELLS/MICROWELL 
C. ANTI-~ +  BCGF STIMULATEC 
10 4  10  s  10  6 
FIG. 4.  The relationship between B cell density in  microwell cultures and  the  magnitude  of 
proliferative responses of B cells. Various numbers of purified peripheral blood B cells ranging from 
103 to 5 ×  105 cells/well were cultured in medium alone (A) or with 15/~g/ml of anti-/~ antibody 
(B) or with 15/zg/ml of anti-/z antibody and 25% vol/vol of BCGF (C). Cultures were incubated for 
3 d;  [3H]thymidine was added  for the last 16 h. Data represent the mean +  SEM of triplicate 
experiments. 
ranging from  10  z to 5  ×  105/well were cultured  with anti-/x antibody  (15/~g/ml)  in 
the  presence  or  absence  of BCGF  (25%  vol/vol),  and  proliferation  of B  cells  was 
measured after 3 d of culture. When B cells were cultured with anti-/~ antibody in the 
absence of BCGF at  a  high cell  density,  usually  as many as  6.25  ×  104 cells/well, 
significant  proliferation  (>108  cpm  of [ZH]thymidine  incorporation)  was  observed 
(Fig.  4 B).  However,  when  B  cells  were cultured  with  anti-/x  antibody  and  BCGF, 
substantial  responses to anti-/t antibody were found with as little as  7.8 X  108 cells/ 
well  (Fig.  4C).  This  relationship  between  cell  density  and  the  requirement  for 
exogenous BCGF in the proliferative response of B cells to anti-/~ stimulation suggests 
that at high cell densities, anti-/~-stimulated B cells receive the required second signal 
for proliferation  from contaminating  accessory cells.  At  low cell  densities  in which 
accessory cells are limited,  exogenous BCGF is required  to deliver this second signal 
to the anti-/x-stimulated B cells. These data confirm those of Howard et al.  (30) in the 
murine model. 
The effect of BCGF on peripheral  blood B  cells co-cultured with various concen- 
trations of anti-/~ antibody is shown in Fig. 5. Purified  1 ×  105 sIg+ cells were cultured 
with  anti-/~  antibody  at  a  final  concentration  ranging  from  1  to  75  ~g/ml  in  the 
presence  or absence  of BCGF  (25%  vol/vol).  In three  separate  experiments,  in  the 
presence of BCGF, substantial  B cell proliferation was observed in an antibody dose- 
dependent  fashion,  with  the  maximal  response  noted  at  15  /xg/ml  of antibody. 
Although  no  proliferation  was  induced  at  low  concentrations  of anti-/x  antibody, 
significant  proliferation  was  observed  at  relatively  high  concentrations  of anti-~ 
antibody  in  the  absence  of BCGF.  Freshly  separated  tonsillar  B  cells  also  showed 
substantial  proliferation in the co-culture system of anti-/~ antibody and BCGF (Fig. 
6). 
Costimulation with Anti-t~ Antibody and BCGF Results in Proliferation of B  Cells without 
Maturation to Ig-secreting Cells.  To more precisely characterize the response of B cells 
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FIG. 5.  Synergistic  effect of low dose of anti-# antibody and BCGF on peripheral blood B cells. 1 
X 10  ~  purified B cells  from three individual normal donors were cultured with various concentrations 
of anti-# antibody in the presence (0)  or absence (C)) of BCGF (25% vol/vol). Cells were also 
cultured with PHA (2 #g/ml) in the presence of anti-# antibody (15 #/ml) or SAC (l:104 dilution). 
Cultures were incubated for 3 d; [aH]thymidine  was added for the last 16 h. Data represent the 
mean + SEM of triplicate experiments. 
blood or tonsillar MNC were cultured with anti-/~ antibody (15/~g/ml)  and BCGF 
(25% vol/vol) and assayed on day 3 for proliferation by measuring the incorporation 
of [3H]thymidine and on day 7 for maturation to Ig-secreting cells by measuring Ig 
(total IgM and IgG)  in the culture supernatants by ELISA. As shown in Table II, 
tonsillar B  cells  cultured with  PWM  and  irradiated  T  cells  showed  the  expected 
polyclonal proliferative response concomitant with polyclonal Ig production, whereas 
B  cells cultured with  anti-/~ antibody and  BCGF  showed  substantial proliferative 
responses without the induction of Ig production. This observation was also made in 
peripheral blood B  cells stimulated with anti-~ antibody in the presence of BCGF. 
These data indicate that although costimulation with anti-hi antibody and monoclonal 
BCGF can induce blast transformation and DNA synthesis, it cannot induce matu- 
ration to Ig synthesis and secretion. 
Relationship  of Cell Size  and State  of In  Vivo  Activation  to Responsiveness  to  BCGF.  In 
virtually all  the  costimulatory assays  performed  with  anti-/~ antibody and  BCGF, 
relatively high background proliferative responses of B cells to BCGF in the absence 
of anti-/~ antibody were  consistently observed  (2-8  X  103  cpm).  This  observation 
prompted us to investigate the possibility that a  B  cell subpopulation in peripheral 
blood or tonsillar lymphocytes had been preactivated in vivo sufficiently to respond 
to BCGF alone in the absence of an in vitro activation signal such as anti-bt antibody. 
To study the potential relationship between B cell subsets and their responsiveness to A.  MURAGUCHI, J.  L.  BUTLER, J.  H.  KEHRL,  AND  A.  S.  FAUCI 
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Fie.  6.  Synergistic effect  of low dose of anti-# antibody and BCGF on tonsillar B cells.  1 X  105 
purified B cells  from tonsils of three subjects were cultured with various concentrations of anti-p 
antibody in the presence (0) or absence (O) of BCGF (25% vol/vol). Cells were also cultured with 
PHA (2 ~g/ml) in the presence of anti-p antibody (15/xg/ml) or SAC (1:104 dilution). Cultures were 
incubated for 3 d; [aH]thymidine was added for the last 16 h. Data represent the mean ±  SEM of 
triplicate experiments. 
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TABLE  II 
Proliferation vs. Differentiation  and Ig Secretion of Human  Tonsillar  B 
Lymphocytes 
Total Ig in cul-  Stimulant*  [ZH]thymidine uptake:~  ture supernatant§ 
X 10 -a cpm  ng/ml 
1.1 ±0.2  9 
Anti-#  0.3 ±  0.1  7 
BCGF  2.4 ±  0.6  14 
Anti-# plus BCGF  21.7 ±  2.3  33 
PWM plus irrT  H  16.8 ±  4.1  >1000 
* 1 x  105 tonsillar B cells were cultured with anti-# (15 #g/ml), BCGF (25% 
vol/vol), PWM  (10 #g/ml), or  1 ×  105 2,000-rad-irradiated autologous T 
cells as indicated. 
~: Uptake of [3H]thymidine was measured on day 3. 
§ Total Ig (IgM and IgG) in each culture supernatant was assayed by ELISA 
on day 7. 
][ Irradiated T cells. 
BCGF  based on the size of B  cells, we used countercurrent  centrifugation-elutriation 
(26)  to obtain  B  cell populations  of different  sizes.  The  cell-size profile of two  B  cell 
subsets  obtained  by  elutriation  is  demonstrated  in  Fig.  7.  Characterization  of the 
surface  markers  of these  unfractionated  or  fractionated  purified  tonsillar  B  cells  is 
summarized  in Table  III. Of note is the fact that almost all of the cells in the fraction 538  ACTIVATION AND  PROLIFERATION OF  HUMAN  B CELL SUBSETS 
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Fro.  7.  Cell-size profile of two B  cell subsets. Tonsillar BCE suspensions were separated into two 
fractions according to cell volume by using counterflow centrifugation-elutriation as described in 
Materials and Methods. Cellular volume was quantitated with a  Coulter Channelyzer. 
TABLE III 
Characterization of Tonsillar B Cells Fractionated by Counterflow Centrifugation 
Surface marker 
Mean vol-  Esterase stain- 
Fraction 
ume  sIg+  Ia+  4F2+  ER+  ing positive 
#3  % 
Unseparated B cells  215  83  88  22  <0. I  <0.1 
Fraction  1  185  92  ND*  <0.1  <0.1  <0.1 
Fraction 2  325  72  ND  85  <0.1  <0.1 
* Not determined. 
of larger B cells (fraction 2) expressed not only slg but also the 4F2 antigen,  which  is 
a  non-HLA, non-Ia cell-surface marker present on human monocytes and a  subset of 
activated but not resting lymphocytes (21, 22), whereas cells in the fraction of smaller 
B  cells  (fraction  1)  did  not  express  4F2  antigen  on  their  surface.  These  separate 
fractions were cultured with or without anti-# antibody (0.6-15/lg/ml)  in the presence 
or absence of BCGF (25% vol/vol), and incorporation of [3H]thymidine was measured 
on  day 3.  Smaller  cells  (fraction  1)  manifested  substantial  proliferative  responses  to 
costimulation  with  anti-#  antibody  and  BCGF,  but  very  little  proliferation  was 
observed  with  anti-/~  antibody  or  BCGF  alone  (Fig.  8).  Larger  B  cells  (fraction  2) 
manifested substantial  proliferative responses to BCGF without  anti-/~ antibody,  and 
the  addition  of anti-/~  antibody  did  not  affect  the  response  to BCGF  (Fig.  8).  This 
observation indicates that small (presumably resting)  B cells need at least two signals 
(anti-/~ antibody  and  BCGF)  for initiation  of proliferation,  whereas  large  (activated) 
B cells need only one signal  (BCGF)  for initiation  of proliferation  or more likely for 
amplification  of the  low  level  of proliferation  that  had  already  been  introduced  in 
vivo. A.  MURAGUCHI,  J.  L.  BUTLER,  J.  H.  KEHRL,  AND  A.  S.  FAUCI 
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FIc.  8.  Effect of anti-# antibody and BCGF on B cells of different  sizes. 1 X  l05 unfractionated B 
cells, smaller B  cells  (fraction  1 in  Fig.  7), and larger B  cells  (fraction  2  in Fig.  7)  obtained  from 
tonsils were cultured with or without anti-~ antibody  (0.6-15/l~/ml)  in the presence (Q) or absence 
(O) of BCGF (25% vol/vol).  Cultures were incubated  for 3 d;  [ H]tbymidine  was added for the last 
16 h. Data represent the mean 4- SEM of triplicate experiments. 
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Discussion 
The present study demonstrates a synergistic relationship between activation signals 
delivered  to human B  cells  in the form  of anti-/~ antibody and proliferative  signals 
delivered by BCGF  for the ultimate proliferation of B  cells.  The BCGF  used was a 
monoclonal protein produced by a  human T-T  cell  hybridoma we  had previously 
described  (20). This particular growth factor sustains proliferation in B cells that are 
already proliferating and induces proliferation in B cells that have been activated but 
are not yet proliferating  (20).  Furthermore, by using size separation techniques, we 
were able to separate  at least two fractions of tonsillar lymphocytes that differed  in 
their  requirement  for  those  activation  signals  that  rendered  them  sensitive  to  the 
proliferative  signals  of  the  monoclonal  BCGF.  Such  observations  have  clear-cut 
implications for our attempts to more precisely delineate the minimal, optimal, and 
synergistic  signals  involved  in  the  activation,  proliferation,  and  differentiation  of 
human B cells. 
With regard  to the use of anti-/~ antibody to activate  human B  cells,  it has been 
proposed in several studies that the binding of specific antigen to slg on B cells triggers 
activation  of the  antigen-specific  B  cells  and  initiates  a  complex  series  of events 
whereby B cells evolve into Ig-producing cells (32). This being the case, cross-linking 
of the sIg on B  cells by anti-Ig antibody directed  against the appropriate sIg could 
activate  B  cells  in  a  polyclonal  manner,  resulting  in  subsequent  proliferation  and 
differentiation  if combined with other appropriate  signals.  In this regard,  Sell  and 540  ACTIVATION  AND PROLIFERATION OF HUMAN B CELL SUBSETS 
Gell (33) initially described the stimulation of blastogenesis of rabbit B cells by anti- 
allotype sera. It has subsequently been demonstrated by Kishimoto et al.  (16,  34)  in 
the rabbit system and by Parker et al. (15) in the murine system, that anti-Ig antibody 
in the presence of T  cell-derived factors induces Ig production in B cells. Since that 
time, anti-Ig antibody has been extensively used to selectively induce the proliferation 
of B  cells, particularly in  the murine system  (35,  36).  However, this approach has 
been less successful in the human system and although there have been several reports 
of human  B  cell  activation  by  anti-Ig,  results  have  been  controversial,  probably 
because  of the  various  types  of anti-Ig  antibodies  used  and  the  differing cellular 
requirements for activation (37-40). 
In  the present study, we used purified B  cells from peripheral  blood or tonsillar 
lymphocytes and the F(ab')2 fraction of goat anti-human  IgM antibody. With  low 
concentrations  of goat  anti-/~  antibody,  the  whole  population  of purified  B  cells 
manifested very little proliferation. However, a  marked synergistic effect on B  cell 
proliferation was noted with anti-# antibody in the presence of BCGF. Regarding the 
question of specific binding of anti-# antibody to the IgM receptor on B cells, it was 
demonstrated  that  the  synergistic  effect of anti-/~  antibody  and  BCGF  on  B  cell 
proliferative responses was  completely inhibited by the addition  of soluble human 
IgM, but not by human IgG (Fig. 2). It is not clear why the addition of 20 #g/ml of 
soluble IgM-enhanced anti-# induced B cell proliferation, but it is quite conceivable 
that  the  immune  complexes  made  up  of IgM  and  anti-#  antibody  enhance  the 
lymphocyte proliferative responses, as previously described (41, 42). 
It has previously been reported that  high concentrations of heterologous F(ab')2 
fragment rabbit anti-# antibody induced B cell proliferation without a  requirement 
for BCGF (40). In that study, Chiorazzi et al. clearly demonstrated that in the absence 
of added BCGF, purified rabbit anti-human IgM or IgG antibodies induced prolif- 
eration of human tonsillar or peripheral blood B cells.  The optimal concentration of 
antibody was  100-400 #g/ml. This requirement for a relatively high concentration of 
antibody to induce BCGF-independent B cell proliferation has also been reported in 
the murine system (35).  Furthermore, cross-linking of slg by large molecules such as 
the particulate SAC also resulted in BCGF-independent B cell proliferation (17).  In 
contrast, in the present study, low concentrations of anti-/1  antibody induced barely 
detectable levels of  proliferation in tonsillar or peripheral blood B cells. In the presence 
of BCGF, however, these same low concentrations of anti-# antibody induced sub- 
stantial proliferation (Figs.  5 and 6). This observation of synergy with low concentra- 
tion anti-# antibody and  BCGF is the same as that  made in the murine model by 
Howard et al.  (30).  Of note is the fact that higher concentrations of anti-/~ antibody 
in our system did indeed induce a certain degree of B cell proliferation in the absence 
of BCGF similar to the BCGF-independent proliferation reported by us (17,  18) with 
SAC and by Chiorazzi et al.  (40)  with high concentrations of rabbit anti-Ig.  These 
observations fit quite well with a more precise delineation of the model of human B 
cell  function  proposed  by  us  and  others  (18,  43).  It  is  likely  that  SAC  or  high 
concentrations of anti-Ig can provide a  powerful enough signal for the B cell to not 
only be activated but  also  to undergo a  degree of self-limited proliferation in  the 
absence  of BCGF.  On  the  other  hand,  a  weaker  triggering  signal  such  as  low 
concentration anti-/~ antibody only provides an activation signal, without driving the 
cell to express the early rounds of proliferation. This signal can, however, induce the A. MURAGUCHI, J. L. BUTLER, J.  H. KEHRL, AND A. S.  FAUCI  541 
B cell to express receptors for BCGF (18), which then allow it to respond synergistically 
to exogenous BCGF by substantial proliferation. Thus it appears that the strength of 
the  initial  activating  signal  in  vitro determines whether  the  B  cell will  go  on  to 
proliferate (in the case of a strong stimulus) as well as whether there will be synergy 
with exogenous factors such as BCGF  (as with weak stimuli).  Furthermore, it was 
shown in the present study by using a low concentration of anti-/z stimulation that (a) 
as  cell density  in  cultures  decreases,  anti-#-induced  B  cell proliferation is  rapidly 
reduced to background levels (Fig. 4 B); and (b) the synergistic effect ofanti-/~ antibody 
and  BCGF  was  observed  in  cell  densities  as  low  as  7.8  X  10a/well,  whereas  no 
proliferation was  observed with  anti-/~  antibody alone  (Fig.  4C).  This observation 
again strongly suggests the requirement of BCGF for a B cell proliferative response to 
a weaker triggering signal. 
In  the  present  study,  costimulation  of B  cells with  anti-#  antibody and  BCGF 
resulted in proliferation without differentiation into Ig-secreting cells (Table II). In 
this regard,  it has recently been reported that  there are separate signals  for B  cell 
proliferation vs.  differentiation in mouse  (14-16)  and  in  man  (17,  18, 43).  We are 
currently  studying  differentiation  factors  derived  from  either  mitogen-stimulated 
MNC  cultures  (29,  44)  or  human  T-T  cell  hybridomas  (20)  which  can  induce 
differentiation in B cells stimulated with anti-/~ antibody and BCGF. 
An observation of particular interest that emerged from the present study was that 
B cells were differentially sensitive on the basis of size to either the activation signal 
delivered by arati-#  antibody or the proliferative signal  delivered by BCGF.  BCGF 
could  directly  stimulate  larger  B  cells  to  proliferate  even  in  the  absence  of the 
activation signal delivered by anti-~ antibody. In fact, anti-~ antibody did not at all 
increase the proliferative response of these larger B  cells to BCGF, which strongly 
suggests that the activation signal was superfluous. Thus, it is highly likely that these 
larger tonsillar B cells were already activated in vivo; they certainly already expressed 
receptors for BCGF, since they proliferated quite well to BCGF alone. In fact, these 
larger B  cells were shown  to be already activated  in  that  they expressed the 4F2 
antigen (Table III) found on activated but not resting lymphocytes (J. H. Kerl and 
A.  S.  Fauci,  manuscript  in  preparation)  (21,  22).  In  contrast, the smaller tonsillar 
lymphocytes did not respond to BCGF alone and hence did not express functional 
receptors for BCGF. Furthermore, they did not express the 4F2 activation antigen 
and they required activation by anti-/x antibody in order to respond by proliferation 
to BCGF.  These data  are consistent with  those reported in  the  murine model by 
DeFranco et al. (45, 46). These authors demonstrated that virtually all resting B cells 
were stimulated by low concentrations of anti-/t antibody to become larger (i.e., to 
proceed from Go phase to G1 phase of the cell cycle), and that  a  subpopulation of 
these cells entered S phase in response to high concentrations of anti-~ antibody or 
lipopolysaccharide. These latter reagents apparently acted directly on the B cells or 
stimulated other cells to produce BCGF, which may be the  actual  stimulus  to G1 
phase B cells to enter S phase  (46).  Anderson and Melchers (47)  have also demon- 
strated a different pattern of the responsiveness of resting and activated (large) B cells 
to nonantigen-specific T  cell factors, with only the activated B  cells being able to 
proliferate and  differentiate in response to such  factors in  the absence of antigen. 
Taken together, these results extend and expand the model of B cell activation with 542  ACTIVATION  AND  PROLIFERATION  OF  HUMAN  B  CELL  SUBSETS 
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F[o.  9.  Proposed scheme of human B cell activation and proliferation. In the in vivo situation, 
certain resting B ceils may be activated by exposure to specific antigen. Upon activation, the cells 
become larger and express  receptors for growth factors.  Thus when B cells are removed from the 
host, they are in various states of activation depending on prior exposure to these various activation 
signals in vivo. In the examination of the B cell repertoire in vitro, certain cells will  have already 
been activated in vivo and thus will  be larger and will  express  activation antigens such as 4F2. 
These activated cells are already sensitive to the proliferative signals delivered by BCGF and will in 
fact proliferate to BCGF without needing an in vitro activation signal such as stimulation with anti- 
IX antibody.  Once  these cells  are  exposed  to BCGF,  they will  proliferate and  go  on  to express 
receptors for a B cell differentiation factor termed BCDF. If exposed to BCDF, they will differentiate 
and secrete Ig.  In contrast, the smaller resting B cell that has not received an activation signal in 
vivo is resistant to direct stimulation by BCGF and does  not express  the 4F2 activation antigen. 
Upon triggering with anti-Ix antibody, the resting B cell becomes larger, expresses  the 4F2 antigen, 
and becomes sensitive to the proliferative signals to BCGF. It thus assumes the same profile of the 
B cell that had been activated in vivo. When this in vitro-activated B cell is exposed to BCGF, it 
proliferates, expresses  receptors for BCDF, and will  differentiate upon exposure to differentiation 
signals. 
regard to the relationship between activation and proliferation (Fig. 9). B  cells require 
activation  in  order  to  express  receptors  for  BCGF  that  are  required  for  sustained 
proliferation.  This  activation  signal  can  be  delivered  by  either  anti-It  ,  which  is  the 
minimal  activation signal  that  results in  virtually  no proliferation  in  the absence of 
exogenous BCGF,  or by high concentration  anti-It antibody  or SAC, which  activates 
cells  and  induces  a  degree  of proliferation  without  exogenous  BCGF.  These  larger 
cells can still respond  to exogenous BCGF  and  thus still express receptors  for BCGF. 
B  cells may  also be activated  in vivo. Complete  activation  that  drives a  cell through 
proliferation as well as differentiation clearly can occur in vivo since spontaneous  Ig- 
secreting  cells  are  routinely  demonstrated  in  vitro  within  the  circulating  B  cell 
repertoire  (48). Lesser degrees of in vivo activation can trigger a  cell to express BCGF 
receptors, such that when  the cells are studied in vitro they respond directly to BCGF 
and  do not require the activation signal of anti-/* antibody. 
Such studies of the combination  of in vivo and in vitro activation of human  B  cells 
using  purified  growth  and  differentiation  factors  produced  from  human  T-T  cell 
hybrids  should  provide  new  and  potentially  important  avenues  of approach  to  the 
delineation of the precise mechanisms  of activation, proliferation, and  differentiation 
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Summary 
The  present  study  demonstrates  the  minimal,  optimal,  and  synergistic  signals 
involved in the activation of normal human peripheral  blood and tonsillar B cells to 
proliferation.  Initial activation signals were delivered to B cells by low concentrations 
of anti-# antibody which did not induce proliferation by themselves. However, marked 
synergy was  seen  when  anti-#  antibody  was  added  to  cultures  in  the  presence  of 
monoclonal B  cell  growth  factor  (BCGF)  obtained  from a  human  T-T cell  hybrid 
such that the B cells underwent substantial  proliferation. This latter proliferation was 
seen without maturation into Ig-secreting cells, which indicates that the BCGF is not 
a  differentiation  signal  but  a  signal  that  drives  the  cell  up  to but  not  beyond  the 
proliferative phase.  Of note was the fact that B  cells reflected differential  sensitivity 
on the basis of size to either the activation signal delivered by anti-# antibody or the 
proliferative signal delivered  by BCGF. BCGF directly stimulated  the larger B  cells 
in the normal tonsillar B cell repertoire to proliferate without the requirement  for an 
in  vitro activation  signal,  which indicates  that  the  cells  had  already received  some 
form of activation signal in vivo. Indeed, these cells expressed the 4F2 antigen found 
on activated but not resting lymphocytes. In contrast, the smaller tonsillar B lympho- 
cytes did  not  express  the 4F2  activation  antigen  and  required  activation  by anti-# 
antibody,  which  did  not  of itself induce  proliferation,  but  which  acted  in  synergy 
with BCGF for substantial  proliferation  of the B  cells.  These studies  thus provide a 
useful model of human B cell activation, proliferation,  and differentiation and allow 
a  more precise delineation of each phase in this cascade. 
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